NEW
Stock Screener with Intrinsic Value
Protagonist Therapeutics, Inc. (PTGX)
Last Price$37.2(1.6%)
Market Cap$2,297.8M
LTM Operating Income
$149.1M
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
Protagonist Therapeutics, Inc. Operating Income
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | ($9,319.0K) | ($14.8M) | ($32.7M) | ($37.9M) | ($42.3M) | ($80.5M) | ($64.5M) | ($125.8M) | ($131.4M) | ($93.7M) |
Overvalued or undervalued?
Check the intrinsic value for PTGX
and see if it's the right time to invest.
Protagonist Therapeutics, Inc. (PTGX) Operating Income comparison analysis
Crunching data... Almost there!
PTGX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
1) What is Protagonist Therapeutics, Inc.'s Operating Income?
As of today, Protagonist Therapeutics, Inc.'s last 12-month Operating Income is $149.1M, based on the financial report for Sep 30, 2024 (Q3 2024).
2) What is Protagonist Therapeutics, Inc.'s Operating Income growth rate?
Over the last year, Protagonist Therapeutics, Inc.'s Operating Income growth was N/A. The average annual Operating Income growth rates for Protagonist Therapeutics, Inc. have been N/A over the past three years, N/A over the past five years.